Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Peptide applications vary across different populations with distinct needs
PMID 33296025 - half-life and pharmacology
Development Background Cagrilintide was developed by Novo Nordisk as part of its efforts to explore novel peptide-based approaches for metabolic studies
Unlike many peptides that degrade rapidly when exposed to gastric acid or enzymatic activity, this sequence demonstrates remarkable resistance to hydrolysis under acidic conditions, a property that has made it an interesting subject for laboratory research and a useful tool for studying peptide stability across a range of experimental conditions
Maintain consistent results across 2026 studies
The Future of Gut-Focused Metabolic Medicine Research into the gutmetabolic axis is expanding rapidly
US$ 28.95
US$ 29.02
US$ 28.30
US$ 23.60
US$ 23.16
US$ 23.05
US$ 27.57
US$ 22.80
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)